DK1817295T3 - Triazolforbindelser, der modulerer HSP90-aktivitet - Google Patents
Triazolforbindelser, der modulerer HSP90-aktivitetInfo
- Publication number
- DK1817295T3 DK1817295T3 DK05851788.9T DK05851788T DK1817295T3 DK 1817295 T3 DK1817295 T3 DK 1817295T3 DK 05851788 T DK05851788 T DK 05851788T DK 1817295 T3 DK1817295 T3 DK 1817295T3
- Authority
- DK
- Denmark
- Prior art keywords
- triazole compounds
- hsp90 activity
- modulate hsp90
- modulate
- activity
- Prior art date
Links
- 101710113864 Heat shock protein 90 Proteins 0.000 title 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 title 1
- -1 Triazole compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62897904P | 2004-11-18 | 2004-11-18 | |
| US70935805P | 2005-08-18 | 2005-08-18 | |
| US72504405P | 2005-10-06 | 2005-10-06 | |
| PCT/US2005/041779 WO2006055760A1 (en) | 2004-11-18 | 2005-11-17 | Triazole compounds that modulate hsp90 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1817295T3 true DK1817295T3 (da) | 2013-02-18 |
Family
ID=35966006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05851788.9T DK1817295T3 (da) | 2004-11-18 | 2005-11-17 | Triazolforbindelser, der modulerer HSP90-aktivitet |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7825148B2 (enExample) |
| EP (3) | EP2298748B1 (enExample) |
| JP (1) | JP4954083B2 (enExample) |
| KR (2) | KR20140006070A (enExample) |
| CN (2) | CN101072759B (enExample) |
| AU (1) | AU2005306484C1 (enExample) |
| BR (1) | BRPI0518315B8 (enExample) |
| CA (1) | CA2586612C (enExample) |
| DK (1) | DK1817295T3 (enExample) |
| ES (2) | ES2594874T3 (enExample) |
| HR (1) | HRP20130095T1 (enExample) |
| IL (1) | IL183108A (enExample) |
| ME (1) | ME01498B (enExample) |
| MX (1) | MX2007005940A (enExample) |
| NZ (1) | NZ555158A (enExample) |
| PL (1) | PL1817295T3 (enExample) |
| PT (1) | PT1817295E (enExample) |
| RS (1) | RS52642B (enExample) |
| TW (1) | TWI380983B (enExample) |
| WO (1) | WO2006055760A1 (enExample) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005063222A1 (ja) * | 2003-12-26 | 2007-07-19 | 協和醗酵工業株式会社 | Ｈｓｐ９０ファミリー蛋白質阻害剤 |
| KR20140006070A (ko) * | 2004-11-18 | 2014-01-15 | 신타 파마슈티칼스 코프. | Ｈｓｐ90 활성을 조절하는 트리아졸 화합물 |
| DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| RU2007137133A (ru) * | 2005-03-09 | 2009-04-20 | Ниппон Каяку Кабусики Кайся (Jp) | Новый ингибитор hsp90 |
| US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
| CA2604042C (en) | 2005-04-13 | 2016-06-21 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP1934185A1 (en) | 2005-08-12 | 2008-06-25 | Synta Pharmaceuticals Corporation | Pyrazole compounds that modulate hsp90 activity |
| US8629285B2 (en) | 2005-08-18 | 2014-01-14 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate HSP90 activity |
| CA2618628C (en) | 2005-08-18 | 2014-11-18 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| WO2007111211A1 (ja) | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
| WO2007139952A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for the preparation of triazole compounds with hsp90 modulating activity |
| CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| CA2653222A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8063083B2 (en) | 2006-05-25 | 2011-11-22 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
| CA2653327A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| AU2007267860B2 (en) * | 2006-05-25 | 2012-08-09 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| EP2035396B1 (en) | 2006-05-25 | 2014-05-14 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2012200157B2 (en) * | 2006-05-25 | 2014-08-21 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| JP5480623B2 (ja) * | 2006-08-17 | 2014-04-23 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| CA2664852A1 (en) * | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of resorcinol derivatives |
| EP2073804B1 (en) | 2006-10-12 | 2017-09-13 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| WO2008051416A2 (en) * | 2006-10-19 | 2008-05-02 | Synta Pharmaceuticals Corp. | Compounds that inhibit the activity of hsp90 for treating infections |
| FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| WO2008057246A2 (en) * | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
| EP2090607B1 (en) | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
| DE102007002715A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| CA2677481C (en) * | 2007-02-08 | 2015-07-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| TW200904417A (en) * | 2007-02-20 | 2009-02-01 | Synta Pharmaceuticals Corp | Triazole compounds that modulate Hsp90 activity |
| US8993608B2 (en) * | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| WO2008153730A2 (en) * | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-met |
| CN101801983B (zh) * | 2007-08-13 | 2014-01-29 | 辛塔制药公司 | 调控hsp90活性的三唑化合物 |
| WO2009041570A1 (ja) | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
| ATE538105T1 (de) | 2007-10-12 | 2012-01-15 | Arqule Inc | Substituierte tetrazolverbindungen und ihre verwendung |
| GB0722680D0 (en) * | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
| KR100947696B1 (ko) * | 2007-11-23 | 2010-03-16 | 재단법인서울대학교산학협력재단 | 1,2,4-트리아졸 유도체를 함유하는 Ｈｓｐ９０ 억제제 및이를 이용한 항암제 |
| NZ587165A (en) * | 2008-02-04 | 2012-03-30 | Mercury Therapeutics Inc | Ampk modulators |
| FR2928645A1 (fr) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CN101977631A (zh) | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
| US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
| WO2009139916A1 (en) * | 2008-05-16 | 2009-11-19 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate hsp90 activity |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| WO2009158026A1 (en) | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| ES2415234T3 (es) | 2008-08-08 | 2013-07-24 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad Hsp90 |
| WO2010017545A2 (en) * | 2008-08-08 | 2010-02-11 | Synta Pharamceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
| AR077405A1 (es) * | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| AU2010308306A1 (en) | 2009-10-19 | 2012-05-10 | Synta Pharmaceuticals Corp. | Combination cancer therapy with HSP90 inhibitory compounds |
| US20130156755A1 (en) * | 2010-04-19 | 2013-06-20 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| US20130172333A1 (en) | 2010-05-20 | 2013-07-04 | Synta Pharmaceuticals Corp. | Formulation and dosing of hsp90 inhibitory compounds |
| AU2011255438A1 (en) | 2010-05-20 | 2013-01-10 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds |
| WO2011149824A1 (en) | 2010-05-24 | 2011-12-01 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| WO2012026433A1 (ja) * | 2010-08-23 | 2012-03-01 | 第一三共株式会社 | 三環性ピラゾロピリミジン誘導体のフリー体結晶 |
| WO2012037072A1 (en) | 2010-09-13 | 2012-03-22 | Synta Pharmaceuticals Corporation | Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients |
| US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
| CN103327976A (zh) | 2010-11-18 | 2013-09-25 | 辛塔医药品有限公司 | 基于缺氧状态预选受试者以用于治疗性治疗 |
| EP2640384A1 (en) | 2010-11-18 | 2013-09-25 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
| US20140005145A1 (en) * | 2010-12-08 | 2014-01-02 | Synta Pharmaceuticals Corp. | Combination breast cancer therapy with hsp90 inhibitory compounds |
| EP2655345B1 (en) | 2010-12-20 | 2015-02-18 | SIGMA-TAU Research Switzerland S.A. | Aryl triazole compounds with antitumoural activity |
| WO2012096919A1 (en) * | 2011-01-11 | 2012-07-19 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| EP2678013A1 (en) * | 2011-02-23 | 2014-01-01 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with radiotherapy |
| JP2014507443A (ja) * | 2011-02-24 | 2014-03-27 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物での前立腺癌治療 |
| WO2012116247A1 (en) | 2011-02-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| US20140228418A1 (en) * | 2011-05-23 | 2014-08-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| US20140315943A1 (en) * | 2011-05-24 | 2014-10-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors |
| US20140194388A1 (en) * | 2011-05-26 | 2014-07-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| AU2012280931A1 (en) | 2011-07-07 | 2014-02-27 | Synta Pharmaceuticals Corp. | Treating cancer with HSP90 inhibitory compounds |
| US20140296176A1 (en) * | 2011-08-19 | 2014-10-02 | Synta Pharmaceuticals Corp. | Combination cancer therapy with an hsp90 inhibitor and an antimetabolite |
| EP2754682B1 (en) | 2011-09-11 | 2017-06-07 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
| JP2014534228A (ja) * | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| CA2854188A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| WO2013148857A1 (en) * | 2012-03-28 | 2013-10-03 | Synta Pharmaceuticals Corp. | Triazole derivatives as hsp90 inhibitors |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| CA2871540A1 (en) | 2012-05-10 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| EP2887804B1 (en) | 2012-05-22 | 2021-01-27 | Trustees of Dartmouth College | Cycloalkanyl[b]indoles useful as glp-1 modulators |
| AU2013331070A1 (en) * | 2012-10-19 | 2015-05-07 | Synta Pharmaceuticals Corp. | Treating polycystic kidney disease with HSP90 inhibitory compounds |
| WO2015038649A1 (en) | 2013-09-10 | 2015-03-19 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| EP3129064B1 (en) | 2014-03-03 | 2020-01-01 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| WO2015167211A1 (ko) * | 2014-04-30 | 2015-11-05 | 경북대학교 산학협력단 | 3-아릴-1,2,4-트라이아졸 유도체 및 이의 용도 |
| KR101711732B1 (ko) * | 2014-04-30 | 2017-03-02 | 경북대학교 산학협력단 | 3-아릴-1,2,4-트라이아졸 유도체 및 이의 용도 |
| US20170231986A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor |
| US20170224819A1 (en) | 2014-08-11 | 2017-08-10 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor |
| EP3179992B1 (en) | 2014-08-11 | 2022-05-11 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
| US10035792B2 (en) * | 2015-01-22 | 2018-07-31 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Resorcinol derivative as HSP90 inhibitor |
| BR112017016973A2 (pt) | 2015-02-09 | 2018-04-03 | Synta Pharmaceuticals Corp. | terapia de combinação de inibidores de hsp90 e inibidores de pd-1 para tratamento de câncer |
| TN2017000483A1 (en) | 2015-05-20 | 2019-04-12 | Amgen Inc | Triazole agonists of the apj receptor. |
| CN106349233B (zh) * | 2015-07-15 | 2021-06-01 | 上海翰森生物医药科技有限公司 | 3,4-二苯基-4h-1,2,4-三唑衍生物及其制备方法和应用 |
| EP3380970B1 (en) | 2015-11-24 | 2023-01-04 | Sanford Burnham Prebys Medical Discovery Institute | Novel azole derivatives as apelin receptor agonist |
| CN108697666A (zh) | 2016-02-29 | 2018-10-23 | 辛塔制药公司 | 用于治疗卵巢癌的组合疗法 |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| CN111875583B (zh) * | 2017-10-17 | 2021-06-15 | 中国科学院上海药物研究所 | 三氮唑衍生物及其制备方法和用途 |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| EP3653611A1 (en) * | 2018-11-15 | 2020-05-20 | Centre National De La Recherche Scientifique | Inhibitors of metallo-beta-lactamases |
| CN113874015B (zh) | 2018-12-21 | 2024-05-24 | 细胞基因公司 | Ripk2的噻吩并吡啶抑制剂 |
| US20220184217A1 (en) * | 2019-04-03 | 2022-06-16 | Tarveda Therapeutics, Inc. | Hsp90-binding conjugates and formulations thereof |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB928919A (en) | 1960-08-16 | 1963-06-19 | Bellon Labor Sa Roger | Triazole derivatives and a process for their preparation |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4178253A (en) | 1977-04-05 | 1979-12-11 | Ciba-Geigy Corporation | Corrosion inhibited lubricant compositions |
| US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| JPS5770820A (en) | 1980-10-20 | 1982-05-01 | Haruo Ogura | Immunoregulating agent |
| JPS5910574A (ja) | 1982-07-07 | 1984-01-20 | Fujisawa Pharmaceut Co Ltd | トリアゾ−ル誘導体およびその製造法 |
| FR2546887B1 (fr) | 1983-05-30 | 1985-08-30 | Paris 7 Universite | Procede de preparation de dihydro-2,4 triazol-1,2,4 thiones-3 disubstituees en positions 4 et 5 et nouveaux composes pouvant etre prepares par ce procede |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4624995A (en) | 1985-04-09 | 1986-11-25 | Minnesota Mining And Manufacturing Company | Triazolinethione-containing polymer |
| US4740568A (en) | 1985-04-09 | 1988-04-26 | Minnesota Mining And Manufacturing Company | Triazolinethione-containing polymer |
| US5436252A (en) | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
| US5006650A (en) | 1987-02-11 | 1991-04-09 | The Upjohn Company | Novel N-1 substituted beta-lactams as antibiotics |
| DE3729070A1 (de) | 1987-09-01 | 1989-03-09 | Bayer Ag | Substituierte triazolinone |
| US5241074A (en) | 1988-05-09 | 1993-08-31 | Bayer Aktiengesellschaft | Sulphonylaminocarbonyltriazolinones |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5219722A (en) | 1990-09-21 | 1993-06-15 | Konica Corporation | Silver halide color photographic light-sensitive material |
| SK278998B6 (sk) | 1991-02-01 | 1998-05-06 | Merck Sharp & Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu, spôsob i |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| ATE205202T1 (de) | 1992-03-13 | 2001-09-15 | Merck Sharp & Dohme | Imidazol-, triazol- und tetrazolderivate |
| TW218017B (enExample) | 1992-04-28 | 1993-12-21 | Takeda Pharm Industry Co Ltd | |
| DE4222771A1 (de) | 1992-07-10 | 1994-01-13 | Bayer Ag | Heterocyclyltriazolinone |
| DE4234801A1 (de) | 1992-10-15 | 1994-04-21 | Bayer Ag | Sulfonylaminocarbonyltriazolinone |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| DE4303376A1 (de) | 1993-02-05 | 1994-08-11 | Bayer Ag | Substituierte Triazolinone |
| DE4303676A1 (de) | 1993-02-09 | 1994-08-11 | Bayer Ag | 1-Aryltriazolin(thi)one |
| DE4411913A1 (de) | 1994-04-07 | 1995-10-12 | Bayer Ag | Substituierte Sulfonylaminocarbonyltriazolinone |
| US5538988A (en) | 1994-04-26 | 1996-07-23 | Martinez; Gregory R. | Benzocycloalkylazolethione derivatives |
| US5489598A (en) | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| JP3372365B2 (ja) | 1994-08-19 | 2003-02-04 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料およびそれを用いた画像形成方法 |
| DE19502579A1 (de) | 1995-01-27 | 1996-08-01 | Bayer Ag | Sulfonylamino(thio)carbonyl-triazolin(thi)one |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| DE19521162A1 (de) | 1995-06-09 | 1996-12-12 | Bayer Ag | N-Aryl-1,2,4-triazolin-5-one |
| DE19525162A1 (de) | 1995-07-11 | 1997-01-16 | Bayer Ag | Sulfonylamino(thio)carbonylverbindungen |
| AU6517196A (en) | 1995-07-13 | 1997-02-10 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
| DE19540737A1 (de) | 1995-11-02 | 1997-05-07 | Bayer Ag | Substituierte Sulfonylamino(thio)carbonylverbindungen |
| DE19609059A1 (de) | 1996-03-08 | 1997-09-11 | Bayer Ag | Substituierte Arylsulfonylamino(thio)carbonyl-triazolin(thi)one |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| ZA974703B (en) | 1996-05-30 | 1997-12-30 | Bayer Ag | Substituted sulfonylamino(thio)carbonyl compounds. |
| TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| DE19632945A1 (de) | 1996-08-16 | 1998-02-19 | Bayer Ag | Substituierte Sulfonylamino(thio)carbonylverbindungen |
| EP0938487A2 (en) | 1996-11-12 | 1999-09-01 | Sepracor, Inc. | 2$i(R),4$i(S),$i(R),$i(S)- AND 2$i(S),4$i(R),$i(R),$i(S)-HYDROXYITRACONAZOLE- AND HYDROXYSAPERCONAZOLE DERIVATIVES |
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| JP3788676B2 (ja) * | 1997-11-11 | 2006-06-21 | 富士写真フイルム株式会社 | 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子 |
| AU3254099A (en) | 1998-03-09 | 1999-09-27 | Basf Aktiengesellschaft | Hetaryl-substituted benzyl phenyl ethers, method for the production thereof, andtheir use for combating harmful fungi and animal pests |
| US6185567B1 (en) * | 1998-05-29 | 2001-02-06 | The Trustees Of The University Of Pennsylvania | Authenticated access to internet based research and data services |
| IT1302034B1 (it) * | 1998-08-31 | 2000-07-20 | Enirisorse Spa | Catalizzatori superacidi solidi per l'isomerizzazione di idrocarburi eprocedimento sol-gel per il loro ottenimento |
| JP2000100570A (ja) | 1998-09-25 | 2000-04-07 | Toray Ind Inc | 発光素子 |
| JP2000284412A (ja) | 1999-03-30 | 2000-10-13 | Fuji Photo Film Co Ltd | 熱現像写真材料 |
| US6492406B1 (en) | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
| US20040110684A1 (en) | 1999-08-02 | 2004-06-10 | Universite Catholique De Louvain | Novel pharmaceutical compositions for modulating angiogenesis |
| CA2429196A1 (en) | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| EP1293503A4 (en) | 2000-05-19 | 2008-04-02 | Astellas Pharma Inc | Triazole derivatives |
| US20030216385A1 (en) | 2000-05-19 | 2003-11-20 | Takahiko Tobe | Triazole derivatives |
| WO2002002123A1 (en) | 2000-06-29 | 2002-01-10 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
| KR20030046397A (ko) | 2000-07-28 | 2003-06-12 | 슬로안-케테링인스티튜트퍼캔서리서치 | 세포증식성 질환 및 바이러스 감염의 치료 방법 |
| AU2877202A (en) | 2000-11-02 | 2002-05-15 | Sloan Kettering Inst Cancer | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
| US20060079493A1 (en) | 2001-03-01 | 2006-04-13 | Lawrence Fritz | Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors |
| US20040235813A1 (en) | 2001-05-03 | 2004-11-25 | Erich Wanker | Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
| JP2004529188A (ja) | 2001-05-23 | 2004-09-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 上昇に関連した癌の治療法 |
| JP4102124B2 (ja) | 2001-08-01 | 2008-06-18 | 富士フイルム株式会社 | ハロゲン化銀乳剤およびハロゲン化銀写真感光材料 |
| WO2003013430A2 (en) | 2001-08-06 | 2003-02-20 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| AU2002361345B8 (en) | 2001-11-28 | 2008-06-26 | Ipsen Pharma S.A.S. | 5-sulphanyl-4H-1,2,4-triazole derivatives and their use as medicine |
| AU2002364566B2 (en) | 2001-12-12 | 2009-03-26 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating HSP90 binding activity |
| DE60222804T2 (de) * | 2001-12-21 | 2008-07-03 | Vernalis (Cambridge) Ltd., Abington | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| CA2475767A1 (en) | 2002-02-07 | 2003-08-14 | The Curators Of The University Of Missouri | Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds |
| GB0207362D0 (en) | 2002-03-28 | 2002-05-08 | Univ Liverpool | Chemotherapy |
| GB0208516D0 (en) | 2002-04-15 | 2002-05-22 | Univ Liverpool | Chemotherapy |
| GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| US7705027B2 (en) | 2003-02-11 | 2010-04-27 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| EP1457499A1 (en) | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
| CA2518836A1 (en) | 2003-03-13 | 2004-09-30 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
| KR101083621B1 (ko) | 2003-03-17 | 2011-11-16 | 쎄코 툴스 에이비 | 상이한 반경을 지닌 코너부를 가지는 인덱서블 인서트 |
| BR0301799A (pt) | 2003-04-09 | 2005-03-22 | Elzo Ferreira | Uso do processo de extração do extrato, da seiva, da tintura, da massa e dos produtos deles derivados, originários da planta xaxim - dicksonia sellowiana - presl - hooker 1844 pertencente à famìlia das dicksoniaceae para emprego nas seguintes áreas e setores: quìmica humana, industrial, farmacológica, biologia humana e animal, medicinal, fitomedicinal, fitoterápica, alopata, alimentìcia, nutricêutico, vitamìnico, dermatológica, cosmética e veterinária |
| EP1615637A1 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| WO2004089415A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| SE0301232D0 (sv) | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
| GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
| US20050020556A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| US20050054625A1 (en) | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors |
| US20050020534A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| US20050026893A1 (en) | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
| US20050020557A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors |
| US7691838B2 (en) | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
| US20050054589A1 (en) | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| DE602004012578T2 (de) | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
| JP2005084612A (ja) | 2003-09-11 | 2005-03-31 | Fuji Photo Film Co Ltd | ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料 |
| JP2007505888A (ja) * | 2003-09-22 | 2007-03-15 | ファイザー インコーポレイテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
| MXPA06003163A (es) | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
| AU2004284420A1 (en) | 2003-09-24 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase |
| US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| JP2007509045A (ja) | 2003-10-18 | 2007-04-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 尿失禁および関連疾患の処置用のｇａｂａアゴニストとしての５−置換２−（フェニルメチル）チオ−４−フェニル−４ｈ−１，２，４−トリアゾール誘導体および関連化合物 |
| JP2007509968A (ja) | 2003-10-28 | 2007-04-19 | ファルマシア・コーポレーション | 新形成を治療または予防するためのｈｓｐ９０阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ |
| WO2005044194A2 (en) | 2003-10-28 | 2005-05-19 | Pharmacia Corporation | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR |
| CA2558224A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| EP1730124A4 (en) * | 2004-03-26 | 2009-04-01 | Amphora Discovery Corp | Certain compounds based on triazole, compositions and applications thereof |
| DE102004039280A1 (de) | 2004-08-13 | 2006-02-23 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| KR20140006070A (ko) * | 2004-11-18 | 2014-01-15 | 신타 파마슈티칼스 코프. | Ｈｓｐ90 활성을 조절하는 트리아졸 화합물 |
| DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| RU2007137133A (ru) | 2005-03-09 | 2009-04-20 | Ниппон Каяку Кабусики Кайся (Jp) | Новый ингибитор hsp90 |
| JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
| US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| EP1934185A1 (en) | 2005-08-12 | 2008-06-25 | Synta Pharmaceuticals Corporation | Pyrazole compounds that modulate hsp90 activity |
| US8629285B2 (en) | 2005-08-18 | 2014-01-14 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate HSP90 activity |
| CA2618628C (en) | 2005-08-18 | 2014-11-18 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2653222A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2007267860B2 (en) | 2006-05-25 | 2012-08-09 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| CA2653327A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| US8063083B2 (en) | 2006-05-25 | 2011-11-22 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
| EP2035396B1 (en) | 2006-05-25 | 2014-05-14 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| JP5480623B2 (ja) * | 2006-08-17 | 2014-04-23 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| WO2008051416A2 (en) | 2006-10-19 | 2008-05-02 | Synta Pharmaceuticals Corp. | Compounds that inhibit the activity of hsp90 for treating infections |
| WO2008057246A2 (en) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| CA2677481C (en) | 2007-02-08 | 2015-07-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| TW200904417A (en) | 2007-02-20 | 2009-02-01 | Synta Pharmaceuticals Corp | Triazole compounds that modulate Hsp90 activity |
| US8993608B2 (en) | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| ES2395114T3 (es) | 2007-03-27 | 2013-02-08 | Synta Pharmaceuticals Corporation | Derivados de triazinona y de diazinona útiles como inhibidores de Hsp90 |
| WO2008153730A2 (en) | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-met |
| CN101801983B (zh) | 2007-08-13 | 2014-01-29 | 辛塔制药公司 | 调控hsp90活性的三唑化合物 |
| US8548104B2 (en) * | 2010-11-23 | 2013-10-01 | Siano Mobile Silicon Ltd. | Receiver with configurable clock frequencies |
-
2005
- 2005-11-17 KR KR1020137030848A patent/KR20140006070A/ko not_active Ceased
- 2005-11-17 ES ES10075452.2T patent/ES2594874T3/es not_active Expired - Lifetime
- 2005-11-17 BR BRPI0518315A patent/BRPI0518315B8/pt active IP Right Grant
- 2005-11-17 PL PL05851788T patent/PL1817295T3/pl unknown
- 2005-11-17 HR HRP20130095TT patent/HRP20130095T1/hr unknown
- 2005-11-17 AU AU2005306484A patent/AU2005306484C1/en not_active Ceased
- 2005-11-17 JP JP2007543263A patent/JP4954083B2/ja not_active Expired - Fee Related
- 2005-11-17 EP EP10075452.2A patent/EP2298748B1/en not_active Expired - Lifetime
- 2005-11-17 PT PT58517889T patent/PT1817295E/pt unknown
- 2005-11-17 MX MX2007005940A patent/MX2007005940A/es active IP Right Grant
- 2005-11-17 ES ES05851788T patent/ES2399241T3/es not_active Expired - Lifetime
- 2005-11-17 WO PCT/US2005/041779 patent/WO2006055760A1/en not_active Ceased
- 2005-11-17 US US11/282,119 patent/US7825148B2/en active Active
- 2005-11-17 EP EP10075465.4A patent/EP2295416B1/en not_active Expired - Lifetime
- 2005-11-17 KR KR1020077013728A patent/KR101374553B1/ko not_active Expired - Fee Related
- 2005-11-17 RS RS20130040A patent/RS52642B/sr unknown
- 2005-11-17 NZ NZ555158A patent/NZ555158A/en not_active IP Right Cessation
- 2005-11-17 ME MEP-2013-16A patent/ME01498B/me unknown
- 2005-11-17 EP EP05851788A patent/EP1817295B1/en not_active Expired - Lifetime
- 2005-11-17 CA CA2586612A patent/CA2586612C/en not_active Expired - Lifetime
- 2005-11-17 CN CN2005800418702A patent/CN101072759B/zh not_active Expired - Fee Related
- 2005-11-17 DK DK05851788.9T patent/DK1817295T3/da active
- 2005-11-17 CN CN201310207740.8A patent/CN103554042B/zh not_active Expired - Fee Related
- 2005-11-18 TW TW094140588A patent/TWI380983B/zh not_active IP Right Cessation
-
2007
- 2007-05-10 IL IL183108A patent/IL183108A/en active IP Right Grant
-
2009
- 2009-10-23 US US12/604,970 patent/US9090569B2/en active Active
-
2010
- 2010-06-14 US US12/815,322 patent/US8362055B2/en not_active Expired - Fee Related
-
2012
- 2012-07-16 US US13/550,324 patent/US8901308B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1817295T3 (da) | Triazolforbindelser, der modulerer HSP90-aktivitet | |
| DK2035396T3 (da) | Triazolforbindelser der modulerer hsp90-aktivitet | |
| NL1029015A1 (nl) | Therapeutische verbindingen. | |
| ATE477257T1 (de) | Piperidinylamino-thienoä2,3-dü- pyrimidinverbindungen | |
| EG24775A (en) | Acetamide compounds as fungicides. | |
| NL1028948A1 (nl) | Ortho gesubstitueerde aryl- of heteroarylamideverbindingen. | |
| DE50309032D1 (de) | Fungizide wirkstoffkombinationen | |
| NL1026958A1 (nl) | Aryl- of heteroarylamideverbindingen. | |
| DE602004027424D1 (de) | Operationsverwaltungsprogramm, operationsverwaltun | |
| ATE422819T1 (de) | Fungizide wirkstoffkombination | |
| NL1031335A1 (nl) | Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen. | |
| NL1030382A1 (nl) | Gesubstitueerde N-sulfonylaminobenzyl-2-fenoxyaceetamide verbindingen. | |
| NL1028193A1 (nl) | Farmaceutisch werkzame verbindingen. | |
| ITMI20042238A1 (it) | Composti per fluoropolirterei | |
| ZA200805137B (en) | Fungicidal active compound combination | |
| DE602005018720D1 (de) | Traktor. | |
| NL1030010A1 (nl) | 4-Amino-gesubstitueerde-2-gesubstitueerde-1,2,3,4- tetrahydrochinolineverbindingen. | |
| ATE542424T1 (de) | Fungizide wirkstoffkombination | |
| NL1031384A1 (nl) | Gesubstitueerde aryl-1,4-pyrazinederivaten. | |
| ES1059518Y (es) | Protector antichupones. | |
| DE502005001784D1 (de) | Fungizide wirkstoffkombinationen | |
| ZA200703956B (en) | Triazole compounds that modulate Hsp90 activity | |
| HK1121154A (en) | Imidazole compounds that modulate hsp90 activity | |
| HK1119706A (en) | Triazole compounds that modulate hsp90 activity | |
| HK1120036A (en) | Pyrazole compounds that modulate hsp90 activity |